Core Insights - CERo Therapeutics has initiated its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML) with the first patient already dosed [1][3][4] - The trial is designed to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations, including those with relapsed/refractory disease and newly diagnosed patients with TP53 mutations [3][4] - The study will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology, highlighting the significance of this clinical milestone [1][4] Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [5] - The company aims to create Chimeric Engulfment Receptor T cells (CER-T) that can potentially treat both hematological malignancies and solid tumors, differentiating its product from existing CAR-T therapies [5] - The lead investigator for the trial is Dr. Abhishek Maiti from The University of Texas MD Anderson Cancer Center, who has collaborated with CERo on preclinical data publication [2][3]
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations